The investment will greatly expand the company’s research and development capacity and is a major win for the Indiana
life sciences industry. Dow AgroSciences expects most of the positions to pay between $65,000 and $95,000 annually.
Dr. Gregory N. Larkin, the former global medical director at Eli Lilly and Co., will replace Dr. Judy Monroe, who is leaving
to become deputy director of the Centers for Disease Control and Prevention.
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Local Dow Chemical subsidiary expects to launch five new biotech products by 2012.
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
Dr. Patrick J. Loehrer Sr. replaces Dr. Stephen D. Williams, the center’s founding director, who died of cancer in February
2009.
With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep
getting higher for Eli Lilly and Co.’s efforts to develop drugs faster and cheaper.
A consumer watchdog group filed a lawsuit Monday against WellPoint’s California subsidiary on behalf of policyholders, claiming
they were pushed to take coverage with fewer benefits and higher deductibles.
Dr. Judy Monroe, after five years as Indiana’s public health leader, will spearhead communication between federal and state
health agencies.
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
Carmel-based insurer swings to a profit, but earnings from operations decline.
The California attorney general has demanded documents from several health insurers, including Indianapolis' WellPoint,
believing that their rate-setting and claims practices might be illegal.
While insurers get the blame for rising health-care costs for consumers, surging fees from hospitals and the growing dominance
of such providers may be just as responsible for driving up expenses, according to a new study examining California's
market.
The ongoing smoking-ban debate is getting a new spark from convention leaders trying to light a fire under
lawmakers, who have been reluctant to approve the kind of comprehensive smoking ban that
health—and now tourism—officials say is needed here.
A former Toyota exec blasts non-family managers for the company’s problems. Are some Indianapolis-area companies better-
or worse-off after families relinquished control?
The House has approved legislation that would ban smoking in public places statewide except casinos and pari-mutuel horse
racing venues.
Amid attacks from Democrats over high executive salaries, Angela Braly testified in Washington, D.C., on Wednesday that big
insurance-premium increases are
the result of growing price tags for hospital care and pharmaceuticals.
California lawmakers grilled Anthem Blue Cross executives on Tuesday about their plan to boost individual insurance premiums
by as much as 39 percent, only to hear them blame the economy and a broken health care system.
Drugmakers, such as Indianapolis-based Eli Lilly and Co., would shoulder $3.3 billion in fees, face ban on pay-for-delay deals
with generic competitor.
CEO Angela Braly is defending individual premium hikes one day before Obama's summit to debate his new reform proposal
with Republicans.
